Psoriasis-associated genetic polymorphism in North Indian population in the CCHCR1 gene and in a genomic segment flanking the HLA-C region

G. Gandhi\textsuperscript{a}, B. Singh Buttar\textsuperscript{a}, L. Alber\textsuperscript{b}, Q. Hasan\textsuperscript{c} and R.K. Aggarwal\textsuperscript{b,∗}
\textsuperscript{a}Department of Human Genetics, Guru Nanak Dev University, Amritsar, India
\textsuperscript{b}Centre for Cellular and Molecular Biology (CSIR), Hyderabad, India
\textsuperscript{c}Department of Genetics and Molecular Medicine, Kamineni Hospitals, Hyderabad, India

Abstract. Psoriasis is a common, chronic, recurrent, inflammatory, hyper proliferative disorder of the skin, which has a relatively high prevalence in the general population (0.6–4.8%). Linkage and association analyses in various populations have revealed a major locus for psoriasis susceptibility, PSORS1, at 6p21.3. Association of the disease with human leukocyte antigen (HLA) Cw6, corneodesmosin (CDSN) and the coiled-coil alpha-helical rod protein-1 (CCHCR1) has also been reported. Though the PSORS1 locus accounts for 30–50% of familial psoriasis in various global population groups, yet no studies have been published from the North Indian population. Some of the SNPs in HLA-C and CCHCR1 genes have been reported as markers for disease susceptibility. Therefore in the present study, DNA samples from psoriasis patients from North India were genotyped for polymorphisms in CCHCR1 and HLA-C genes. The allele frequencies were calculated for patients and controls, and were compared for odds ratio and confidence interval values. SNP \textsuperscript{n.7*22222} (rs12208888), SNP \textsuperscript{n.7*22333} (rs12216025), SNP \textsuperscript{n.9*24118} (rs10456057), CCHCR1\textsuperscript{386} (rs130065), CCHCR1\textsuperscript{404} (rs130076) and CCHCR1\textsuperscript{1364} (rs130071) were found to be significant in psoriasis patients. Linkage disequilibrium analysis revealed two haplotypes (\textsuperscript{rs12208888, rs2844608, rs12216025, rs10456057, rs130065, rs130066, rs130068, rs130269, rs12208888, rs2844608, rs12216025, rs10456057, rs130065, rs130066, rs130068, rs130269, rs130071}) as highly susceptible haplotypes for psoriasis in the cohort studied. Preliminary analysis of the data also suggests the possibilities of ethnic group specific disease related polymorphisms, pending validation in future studies.

Keywords: Psoriasis, SNP Polymorphism, North-Indian, CCHCR1 gene, HLA-C gene

1. Introduction

Psoriasis (MIM *177900) is one of the most prevalent immune-mediated skin diseases in adults occurring at a frequency of 1–2% among Caucasians and with a lower frequency (0.1%) in Asians [6,7]. In India, the prevalence of psoriasis has recently been inferred as varying from 0.44 to 2.80% [14]. The disease is due to the keratinocyte hyper proliferation, and is characterized by red scaly lesions either localized or widespread in extent on the extensor surfaces. The patients have the typical silvery white scales, which vary in numbers. Psoriasis may be erythrodermic, palmo-plantar, vulgaris, inverse type or guttate, albeit the most common phenotype is psoriasis vulgaris accounting for 80–90% of the cases [23].

Genetic-environmental interactions have been proposed as a cause of psoriasis. Twin and family studies suggest a heritability of 60–90%. It is a genetically heterogeneous condition [8,15,17,20]. Genome-wide scans have indicated that 10–20 chromosomal regions harbour psoriasis susceptibility genes; further-
more, genetic predisposition is also suggested in studies indicating linkage to the Human Leukocyte Antigens (HLA) [16,19,20,24,26–29].

Several psoriasis susceptibility loci (PSORS1-9) have been mapped to different chromosomes. Among these, PSORS1 at 6p21.3 has been proposed to be the major candidate locus along with HLA complex [20, 37]. A study in 171 nuclear families revealed a 10 kb core risk haplotype as the PSORS1 susceptibility locus near to HLA-C [37]. This PSORS1 gene has been reported in different ethnic groups. An association of the disease has also been reported with human leukocyte antigen Cw6 and other genes like, corneodesmosin (CDSN) and the coiled-coil alpha-helical rod protein-1 (CCHCR1). Overall the PSORS1 disease susceptible region contains three genes: HLA-C (Human Leukocyte Antigen-C; OMIM *142840), CCHCR1 and CDSN. HLA-Cw*6 allele is involved with psoriasis-related immune response and has been observed as a significant marker for psoriasis risk prediction [1,11]. Based on both, population- and family-based association analyses of haplotypes and by exclusion analysis of recombinant haplotypes in Hans Chinese, Fan et al. [18] refined the PSORS1 gene to a region with HLA-C as was suggested originally by Nair et al. [30].

The CCHCR1 (OMIM*605310) gene located 110 kb telomeric to HLA-C consists of 18 exons stretching over 14.7 kb. The CCHCR1 gene is highly polymorphic and one of its alleles, CCHCR1*WWCC, is suggested to be directly related to the keratinocyte proliferation [35]. Asumalashi et al. [3] identified two SNPs in CCHCR1 that were associated significantly with psoriasis in Finnish families. They also observed an over expression of CCHCR1 gene in keratinocytes of psoriatic lesions implying a potential role of this in the pathogenesis of psoriasis. Genotyping of 419 psoriasis families further revealed that CCHCR1*WWCC (four SNPs, 2 each in exons 4 and 10) and HLA-Cw*6 allele were associated with psoriasis [4].

A genome scan of the 220-kb region (at chromosome 6p21) across 171 family-based trios of European origin, identified 59 SNPs (18 in coding and 41 in non-coding regions), of which two SNPs (n.7 and n.9 lying 7 and 4 kb proximal to HLA-C, respectively) were found to exhibit highly significant association ($p < 10^{-9}$), suggesting these two SNPs as markers for psoriasis susceptibility [37]. This observation was also replicated in a Gujarati Indian case/control study [4]. More recently, Chang et al. [12] explored the above two SNPs of the CCHCR1 gene, along with HLA-CW*0602 by direct sequencing for disease association and showed that the CCHCR1 gene’s SNP n.7*A and SNP n.9*C, as well as, CW*0602 were major susceptibility markers for psoriasis in Chinese patients. Most of these studies showing PSORS1 association with the disease have been based on European/Caucasian and Chinese populations. There is no study from India or information available for Indian populations, except for one European study wherein some subjects of Indian Gujarati descent were also analyzed [10]. Therefore, the present study was carried out to ascertain the association(s), if any, by genotyping markers representing HLA-C region (SNPs n.7, n.9) and CCHCR1 gene (exons 4 and 10) with psoriasis in Indian patients mainly from North India (visiting a local medical institute in Amritsar, Punjab), and a few cases from Hyderabad, Andhra Pradesh.

2. Materials and methods

A case-control study design was used and the control group was adequately matched with the patient group. A record of the population sub-structure was also maintained. To reduce the effect of population stratification (confounding by ethnicity), family-based controls were also used [25]; though, these are also not without bias, because of over- matching and environment-sharing [34].

Psoriasis patients ($n = 44$) and controls ($n = 28$; 18 were normal healthy controls and 10 were positive controls viz. first-degree relatives of psoriasis patients from Punjab) were investigated for genetic polymorphism-disease association(s).

2.1. Subjects

Psoriasis patients were contacted from Skin and Tuberculosis ward, Sri Guru Ram Das Institute of Medical Sciences and Research Charitable Hospital, Amritsar during July- Dec.2005. In addition, three patients were from Kamineni Hospitals Ltd., Hyderabad, representing North Indians living in Andhra Pradesh. All the patients were diagnosed by the dermatologists but were not allotted any Psoriasis severity index (PASI) score. In each case, blood samples were collected after informed written consent. The study was approved by the Institutional Ethics Committee of each of the collaborating institutes.
2.2. Methods

Intravenous blood samples were obtained by venipuncture for all subjects in EDTA (0.5M) vacutainers, and transported to the laboratory on ice for molecular analysis. Whole blood samples were processed to obtain genomic DNA using standard procedures. DNA samples were quantified and checked by agarose gel electrophoresis.

For each of the test domains, the primer pairs were designed from the database retrieved sequences of CCHCR1 gene (GenBank Accession no. AC004195) and HLA-C region (GenBank Accession no. AC004204) using Gene Tool software (www.biotools.com), and custom synthesized by Bioserve, Hyderabad, India (Table 1). These primers were named as: Pso1F/R, Pso2F/R for the HLA-C and Pso3F/R, Pso4F/R for CCHCR1 gene to target amplicon sizes of 272 bp, 376 bp, 445 bp, 420 bp, respectively (Table 1). All primers were designed such (long lengths and high GC content) that the PCR could be carried out under relatively higher stringency/annealing temperature. Further, each of the amplicon was sequenced for both the strands. These measures were taken to avoid the possible noise from the non-target HLA regions having nearly similar sequences.

2.3. PCR amplification

PCR amplifications were carried out in 15 µl reactions, each containing ~5.0 ng of genomic DNA, 5 pmol of forward/reverse primer, 150 µM dNTPs, 1x PCR buffer [500 mM KCl, 100 mM Tris-HCl pH 8.3], 1.5 mM MgCl₂ and 1 unit Taq DNA polymerase in PTC-200 thermal cycler (MJ Research). The amplification profile comprised an initial denaturation step of 95°C for 3 min, followed by 36 three-step cycles of: denaturation at 94°C for 45 sec, annealing at 57°C for 1 min, extension at 72°C for 2 min, and a final extension at 72°C for 5 min. The PCR products were checked on 1.5% agarose gel before sequencing.

2.4. Sequencing

PCR products obtained were directly sequenced for both the strands by fluorescent di-deoxy-terminator chemistry (BigDye, Applied Biosystems) following manufacturer’s instructions on an ABI PRISM 3700 automated DNA sequencer. A total of 288 nucleotide sequences (obtained for the 72 study subjects for the four domains) were deposited in the NCBI core nucleotide database under accession numbers EF055578 to EF055865. These sequences were then looked for polymorphisms by comparing with the genomic reference using the Auto assembler software (ABI, Applied Biosystems).

2.5. Statistical analyses

Statistical analyses were carried out with the help of GOLD Software (http://www.sph.umich.edu/csg/abecasis/gold/index.html; for linkage disequilibrium -D' values) and Medcalc Software (www.MedCalc.be) for odds ratio, CI (Confidence Interval) values and p-values. Bonferroni correction was also used to get stringent p values.

3. Results

There were 27 psoriasis male patients with mean age of 38.90 y (7–80 y) and 17 female patients with mean age of 38.50 y (25–60y), whereas controls (n = 28) comprised 16 males with mean age of 35.60 y and 12 females with mean age of 34.54 y (Table 2). Among the patients, there were 41 with psoriasis vulgaris and three palmo-plantar cases. Early onset (≤ 40y) of the disease was predominant (n = 35) than the late (> 40y) onset for which there were nine patients (Table 2).

4. Study of polymorphic sites

Seventy-two subjects were analyzed by sequencing for the four polymorphic sites of the HLA-C region
Table 2: Clinical Characteristics of Psoriasis Patients

| Characteristics/range | Patients | Controls |
|-----------------------|----------|----------|
|                       | Males    | Females  | Total    | Males    | Females  | Total    |
| Age (years)           |          |          |          |          |          |          |
| ≤ 30                  | 12 (27.27) | 6 (13.64) | 18 (40.90) | 11 (39.29) | 5 (17.86) | 16 (57.14) |
| 31 ≤ 80               | 15 (34.09) | 11 (25.00) | 26 (59.09) | 5 (17.86) | 7 (25.00) | 12 (42.86) |
| Age-of-onset (years)  |          |          |          |          |          |          |
| < 40                  | 21 (47.55) | 14 (31.82) | 35 (79.55) | 5 (17.86) | 7 (25.00) | 12 (42.86) |
| ≥ 40                  | 6 (13.64) | 3 (6.82) | 9 (20.41) |          |          |          |
| Distortion of nails   | Present  | 9 (20.45) | 5 (11.36) | 14 (31.82) |          |          |
|                      |          |          |          |          |          |          |
|                      | Summer   | 26 (59.09) | 16 (36.36) | 42 (95.45) |          |          |
|                      |          |          |          |          |          |          |
|                      | Family history | 6 (25.00) | 5 (11.36) | 11 (36.36) |          |          |
|                      |          |          |          |          |          |          |
|                      | Type of Psoriasis | 26 (59.09) | 15 (34.09) | 41 (93.18) |          |          |
|                      |          |          |          |          |          |          |
|                      | Population Sub-groups | 1 (2.22) | 2 (4.55) | 3 (6.82) |          |          |
|                      |          |          |          |          |          |          |

*Number of subjects; value in parenthesis is (%).

(SNPs n.7 and n.9) and CCHCR1 gene (exons 4, 10), thus resulting in a total of 288 nucleotide sequences [NCBI accession numbers EF055578 to EF055865]. Target and/or novel SNPs, and genotypes significantly varying from control are presented in Table 3.

4.1. HLA-C region

The region was found to be highly polymorphic; a total of 30 polymorphic sites were observed out of which 22 sites were present around SNP n.7 and eight sites around SNP n.9. Out of these, four sites (22211*G, 22222*A, 22238*G, 22333*G) around SNP n.7 and two sites (24118*C, 24134*T) around SNP n.9 were associated with disease phenotype. The sites 22222*A (rs12208888) and 22333*G (rs12216025) in SNP n.7 were significantly associated (Tables 4, 5). The allele 22222*A (rs12208888) was 42.04% in patients vs. 21.42% in controls and was significantly associated with psoriasis (OR 2.66; CI 1.23–5.72, \( p \leq 0.01 \)). Interestingly, a similar significant \( (p \leq 0.01 \) level) association was seen in patients for the 22333*G allele frequency in patients was 40.91% and 8.93% in controls (Table 4).

4.2. CCHCR1 gene

This region was less polymorphic compared to the HLA-C region and exhibited a total of 11 polymorphic sites: 6 in exon 4 and 5 in exon 10.

4.2.1. Exon 4

Five out of six sites (CCHCR1_384*A, CCHCR1_386*T, CCHCR1_404*T, CCHCR1_556*G, CCHCR1_571*C) were associated with psoriasis but only CCHCR1_386*T and CCHCR1_404*T (rs130065, rs130076) showed a statistically significant association (Table 5). Genotypic analysis at CCHCR1_386*T (rs130065) revealed an allele frequency of 37.50% in patients and 10.71% in controls (OR 5.00; CI value 1.93–12.93, \( p \leq 0.001 \)). The C to T alteration changes the amino acid from normal Arg to Trp. The allele frequency at the CCHCR1_404*T (rs130076) in patients was also higher (44.30%) than in controls (10.71%) and highly significant with odds ratio 6.63 (CI value 2.57–17.07, \( p \leq 0.001 \)).

4.2.2. Exon 10

Four of the five sites (CCHCR1_1328*C, CCHCR1_1329*A, CCHCR1_1354*T and CCHCR1_1364*C) in this exon showed association with psoriasis; of this 1364*C (rs130071) was higher (48.86%) and significantly significant with odds ratio 3.16 (CI 1.49–6.67) in patients when compared to controls (23.21%).

4.3. Linkage disequilibrium

Linkage disequilibrium is the non-random association of alleles at linked loci and can be calculated as the coefficient of linkage disequilibrium, D; this is the difference between the observed and expected haplotype frequency under statistical independence depending on allele frequencies. In the present study, a total of 15 markers forming part of HLA-C region (4 in SNP n.7 and 2 in SNP n.9) and of CCHCR1 gene (5 in exon 4 and 4 in exon 10) were studied. In order to calculate inter-marker linkage disequilibrium, the Graphical Overview of Linkage Disequilibrium (GOLD) software was used. Distances between
Table 3

Significant Genotypes ($p \leq 0.01$) observed in Psoriasis Patients and control subjects in the present study

| Genotypes                  | HLA-C (Human Leukocyte Antigen-C) | CCHCR1 (Coiled-coil alpha-helical rod protein 1) |
|----------------------------|-----------------------------------|-----------------------------------------------|
|                            | Patients | Controls | Patients | Controls | Patients | Controls | Patients | Controls |
|                            | SNPn.7    | SNPn.7    | SNPn.9    | Exon 4    | SNPn.9    | Exon 10   |
|                            | 22222*  | 22333*  | 22222*  | 22333*  | 24118*  | 386*  | 404*  | 386*  | 404*  | 1364*  |
|                            | (G→A)  | (A→G)    | (G→A)  | (A→G)    | (T→C) | (C→T)   | (C→T)   | (C→T)   | (T→C)   |
| Homozygous wild            | GG-15 | AA-15 | GG-19 | AA-19 | TT-14 | TT-24 | CC-15 | CC-13 | CC-23 | CC-23 | TT-12 | TT-16 |
| Heterozygous mutant        | AG-21 | AG-21 | AG-6 | AG-6 | CT-24 | CT-3 | CT-25 | CT-23 | CT-4 | CT-4 | CT-21 | CT-11 |
| Homozygous mutant          | AA-8 | GG-8 | AA-3 | GG-3 | CC-6 | CC-1 | TT-4 | TT-8 | TT-1 | TT-1 | CC-11 | CC-1  |

Population Sub groups (Homozygous mutant)

|       | Jat Sikh | Ramgarhia Sikh | Brahmin | Majbi Sikh |
|-------|----------|----------------|---------|------------|
|       | 3        | 2              | 2       | 3          |
|       | 3        | 2              | 2       | 1          |
|       | 1        | 1              | 2       | 1          |
|       | 1        | 1              | 2       | 1          |

C. Gandhi et al. / Psoriasis-associated Genetic Polymorphism in North Indian population
Table 4

| Allele | Patients | Controls | odds ratio | 95 % CI value | p-value |
|--------|----------|----------|------------|---------------|---------|
| SNPn.7 |          |          |            |               |         |
| 22211 A → G (rs2844607) ALL | 89.70% (79/88) | 85.71% (48/56) | 1.46 | 0.53–4.04 | 0.463 |
| Early Onset | 91.43% (64/70) | 1.77 | 0.38–5.46 | 0.315 |
| 22222 G → A (rs12208888) ALL | 42.00% (37/88) | 21.42% (12/56) | 2.66 | 1.23–5.72 | **0.012** |
| Early Onset | 44.00% (34/70) | 1.77 | 0.58–5.46 | 0.315 |
| 22238 A → G (rs2844608) ALL | 69.30% (61/88) | 66.07% (37/56) | 1.16 | 0.56–2.37 | 0.683 |
| Early Onset | 70.00% (49/70) | 1.19 | 0.56–2.54 | 0.638 |
| 22333 A → G (rs12216025) ALL | 42.00% (37/88) | 21.43% (12/56) | 2.66 | 1.23–5.72 | **0.012** |
| Early Onset | 48.57% (34/70) | 3.46 | 1.56–7.64 | 0.002* |
| SNPn.9 |          |          |            |               |         |
| 24118 T → C (rs10456057) ALL | 40.91% (36/88) | 8.93% (5/56) | 7.06 | 2.56–19.42 | **0.0002** |
| Early Onset | 41.40% (29/70) | 8.10 | 2.88–22.76 | **0.0001** |
| 24134 G → T (novel) ALL | 12.50% (11/88) | 3.57% (2/56) | 3.85 | 0.82–18.10 | 0.087 |
| Early Onset | 14.28% (10/70) | 4.50 | 0.94–21.45 | 0.059 |

Significant p-values (⩽ 0.05) are highlighted in bold; * Statistical significance was also established after Bonferroni correction.

Table 5

| Allele | Patients | Controls | odds ratio | 95 % CI value | p-value |
|--------|----------|----------|------------|---------------|---------|
| Exon 4 |          |          |            |               |         |
| CCHCR1_384A (rs130075) ALL | 3.40% (3/88) | 3.57% (2/56) | 0.95 | 0.15–5.88 | 0.958 |
| Early Onset | 2.85% (2/70) | – | 0.79 | 0.10–5.82 | 0.820 |
| CCHCR1_386A (rs130065) ALL | 37.50% (33/88) | 10.71% (6/56) | 5.00 | 1.93–12.93 | **0.0009** |
| Early Onset | 41.42% (29/70) | – | 5.89 | 2.23–15.56 | **0.0003** |
| CCHCR1_404A (rs130076) ALL | 44.30% (39/88) | 10.71% (6/56) | 6.66 | 2.57–17.07 | **0.0001** |
| Early Onset | 47.14% (33/70) | – | 7.43 | 2.82–19.57 | **0.0001** |
| CCHCR1_556A (rs130077) ALL | 5.68% (5/88) | 0% (0/56) | – | – | – |
| Early Onset | 4.28% (3/70) | – | – | – | – |
| CCHCR1_571A (rs130066) ALL | 20.45% (18/88) | 16.07% (6/56) | 1.45 | 0.477–4.44 | 0.508 |
| Early Onset | 22.85% (16/70) | – | 0.62 | 0.28–1.37 | 0.245 |
| Exon 10 |          |          |            |               |         |
| CCHCR1_1328C (rs130068) ALL | 37.50% (33/88) | 51.78% (29/56) | 0.55 | 0.28–1.10 | 0.092 |
| Early Onset | 35.71% (25/70) | – | 0.51 | 0.25–1.05 | 0.071 |
| CCHCR1_1329A (rs130269) ALL | 12.50% (11/88) | 8.92% (5/56) | 1.45 | 0.477–4.44 | 0.508 |
| Early Onset | 15.71% (11/70) | – | 1.90 | 0.61–5.83 | 0.261 |
| CCHCR1_1354T (rs130070) ALL | 2.27% (2/88) | 5.35% (3/56) | 0.41 | 0.06–2.54 | 0.338 |
| Early Onset | 0.0% (0/70) | – | – | – | – |
| CCHCR1_1364C (rs130071) ALL | 48.86% (43/88) | 23.21% (13/56) | 3.16 | 1.49–6.67 | **0.002** |
| Early Onset | 51.42% (36/70) | – | 3.50 | 1.60–7.62 | **0.001** |

Significant p-values (⩽ 0.05) are highlighted in bold; * Statistical significance was also established after Bonferroni correction.

the markers were calculated in base pairs with the help of reference sequence from the NCBI database (accession number BA000025.2), which covers all the SNPs together. On the basis of significant D’ values, nine haplotypes were generated in control individuals and 14 haplotypes in patients which were highly significant (Figs 1, 2). Though individual allele frequencies may not increase the disease risk but in combination they may contribute to the development of Psoriasis. In the controls, only very few alleles were in linkage disequilibrium with each other. This may be due to the fact that a few controls were first-degree relatives having similar parental origin. Hence the markers showing LD may be the susceptible alleles in this patient group or generally, individuals with these alleles have a higher chance to be affected with psoriasis.

5. Ethnicity and psoriasis

The subjects (patients and controls) analyzed in the present study comprised four different ethnic groups, of which the largest group was of the Jat Sikhs (Table 2). Hence, an attempt was made to see if any of the observed polymorphisms were associated with ethnicity. Interestingly, all the three observed HLA-C SNPs n.7 and n.9 polymorphisms i.e., 22222G*A, 22333A*G, 24118T*C (rs12208888, rs12216025, rs10456057)
were significantly associated with psoriasis in patients of the ethnic groups: Jat Sikhs, Brahmmins and Majbi Sikhs, but none in the Ramgarhia Sikhs. A similar ethnic propensity was apparent for the disease-related polymorphisms observed only in the exon-4 and not in the exon-10 of CCHCR1 gene. Disease-related polymorphisms CCHCR1 386C*T and CCHCR1 404C*T (rs130065, rs130076) were seen only in Brahmin and Majbi Sikh patients; none in Jat Sikhs and, equally in patient/control samples of Ramgarhia Sikhs (Table 3).

6. Discussion

Psoriasis, an immune-mediated skin disease, is suggested to be highly heritable and genetically heterogeneous [8,15–17,20]. A perusal of a number of fine mapping studies on different global populations suggests a critical region of about 300 kb for PSORS1, containing HLA-C and a few other genes/critical regions viz., a 285-kb region between the markers tn821 and HLA-C [5]; a 111-kb interval telomeric to HLA-C in the Japanese patients [27]; a 46-kb interval telomeric to HLA-C in Caucasian and Japanese populations [24]; a 70-kb region around the CDSN gene in a Sardinian population [32]; a haplotype block harboring HLA-C but distinct from CDSN and CCHCR1 [21], and a 224-kb region in an American Caucasian population [30]. HLA-Cw*0602 was recognized as significantly associated with Psoriasis and as the marker that confers the highest risk for the disease [3,26].

In the present study, psoriasis patients were investigated for four susceptible markers in the PSORS1 region i.e., HLA-C region (SNPs n.7 and n.9) and CCHCR1 gene (exons 4 and 10). Direct sequence based polymorphism analysis revealed that the sites SNP n.7*22222, SNP n.7*22333, SNP n.9*24118 of HLA-C region and -386, -404 and -1364 of CCHCR1 gene were significantly associated in the psoriasis patients tested in this study (Table 3).

The results from the present study are generally in agreement with the published studies. The PSORS1 locus contributes a 35–50 % relative risk of developing familial psoriasis [9,29,36] and HLA association analyses also support the importance of the PSORS1 locus in psoriasis susceptibility, especially its tight association with the HLA-Cw*6 allele.

Genome analysis of 220-kb region at chromosome 6p21 identified two HLA-C SNPs n.7 and n.9 as highly significant (p < 10−9) markers for disease susceptibility in Finnish population, and some individuals of Gujarati Indian descent [37]. Polymorphisms in CCHCR1 gene, as well as HLA-C region (SNP n.7*A, SNP n.9*C, CW*0602) as major susceptibility markers.
Haplotype-based association analysis revealed SNP n.7*A–SNPn9*C–Cw*0602–CCHCR1*386*T–CCHCR1*404*T–CCHCR1*1802*T–CCHCR1*2406*G as a major susceptibility haplotype. Two of the SNPs (CCHCR1*386*T, CCHCR1*404*T) observed in the Chinese study [12] were previously indicated as susceptible SNPs in a Finnish population [3]. In subsequent studies Asumalaiti et al. [2,4] demonstrated an association of CCHCR1*WWCC with psoriasis and also with the HLA-Cw*6 allele. They reported association of HLA-CW*6, CCHCR1*WWCC, and CDSN*5 genes with clinical variants of psoriasis (guttate psoriasis and palmoplantar psoriasis); but they did not observe any apparent correlation with the age of onset for disease. Moreover, their analysis suggested that psoriasis vulgaris and guttate psoriasis have a similar genetic basis (albeit the latter exhibits a stronger association) with PSORSI susceptibility alleles: HLA-CW*6, CCHCR1*WWCC, and CDSN*5 while palmoplantar psoriasis appeared to be a distinct disorder.

For psoriasis were also indicated in a Chinese population [12].

There were three palmo-plantar cases and 35 patients with early age-of-onset in the present study (Table 2). The data for these subjects when compared with the remaining patients/controls, suggest an apparent, significant association of psoriasis in early onset patients with HLA-C region (rs1220888, rs12216025 in SNP n.7 and rs10456057 in SNP n.9) and CCHCR1 gene (rs130065, rs130076 in exon 4 and rs130068, rs130071 in exon 10). Similarly, in the palmoplantar cases, the data suggest an association with homozygous risk alleles: 22211*G, 22238*A (rs1220888, rs2844608) and 404*C, 571*C, 1328*T, 1364*T (rs130076, rs130066, rs130068, rs130071), and heterozygous alleles: 22222*G, 22333*A, 24118*T (rs1220888, rs12216025, rs10456057) and 386*C, 1328*T, 1329*G, 1364*T (rs130065, rs130068, rs130269, rs130701), of HLA-C and CCHCR1 genes, respectively. (The early onset (< 40 years) patients had severe psoriasis while milder symptoms were present in late onset patients. Strong HLA associations in type I psoriasis and much weaker HLA association in late onset (≥ 40 years) has been documented [12,13,22,33].

In the present study, Linkage disequilibrium test (D' values) revealed two haplotypes viz: SNPn.7,22222*A–SNPn.7,22238*G–SNPn.7,22333*G–SNPn.9,24118*G–CCHCR1*386*T–CCHCR1*571*C–CCHCR1*328*C–CCHCR1*329*A (rs1220888, rs2844608, rs12216025, rs10456057, rs130065, rs130068, rs130269) and SNPn.7,22222*A–SNPn.7,22238*G–SNPn.7,22333*G–CCHCR1*404*T–CCHCR1*571*C–CCHCR1*328*C–CCHCR1*329*A–CCHCR1*364*T (rs1220888, rs2844608, rs12216025, rs130065, rs130068, rs130066, rs130269, rs130701) as highly susceptible major haplotypes for psoriasis in the cohort.
studied. The alleles found significant in the present study were also associated in the Chinese population [12], with the exception of SNPn.7.222111*G (rs28 44607) and SNPn.7.22238*G (rs2844608) which did not show any association with psoriasis in the Indian patients, and the allele CCHCR1_1364*T (rs130071) which was significant in the present study but not in the Chinese patients.

The people of North India are predominantly Indo-Aryan, and include various ethnic groups such as Jats, Rajputs, Gujjars, Ahirs, Khattirs, Kambojs, Banias and Dalits. Sikhs who are mainly found in the Punjab region of India refer to themselves as Jat Sikhs, Mazabhi Sikhs, Ramgarhia Sikhs (http://www.hindubooks.org/sudheer birodkar/hindu_history/castevedic.html). A critical look at the data obtained in the present study suggests apparent associations between some of the identified disease-related polymorphisms of both HLA-C and CCHCR1 genes with some of the ethnic group(s) analyzed in this study. Although, the significance of these observations is limited due to the small sample size, yet these provide interesting possibilities of developing ethnic- group- specific diagnostic/genetic markers of psoriasis. This would need further extended validation studies with larger sample size.

Given the genetic heterogenous etiology of psoriasis and gene-environment interactions, more exhaustive research would be required to identify stable biomarkers and realize their potential in disease prediction and/or personalized medicine that is coming of age. Similarly, exhaustive functional studies are needed to determine the mechanism of action of the disease-causing candidate genes [19], including that of the CCHCR1 protein in psoriasis pathogenesis.

Acknowledgements

We are indebted to the psoriasis patients and controls who participated in this study, to Dr. P.S. Girgila (of Sri Guru Ram Das Institute of Medical Sciences and Research Charitable Hospital, Amritsar) for diagnosing the patients, Dr. Badaruddoza for helping with data analysis, and the Director, CCMB (CSIR) for permission to use DNA sequencing facilities. This work was supported by departmental grants from GNDU.

Electronic-Database Information

Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.nlm.nih.gov/Omim/ (for psoriasis [MIM* 177900], HLA-C [MIM *142840] and CCHCR1 [MIM *605310]). A set of 288 nucleotide sequences (generated for the 72 study subjects in the study) are deposited in the NCBI sequence database with accession numbers- EF055578 to EF055865.

References

[1] K.S. Amr, A.H. Weshahy, El Hadidi, F. Mahmoud, A. El Hamid et al., A Pilot Study of HLA-Cw6 Association with Egyptian Psoriatic Patients, J Medicine Medical Sci 5 (2010), 25–29.
[2] K. Asumalahti, M. Ameen, S. Suomela, E. Hagforsen, G. Michaëlsson et al., Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis, J Invest Dermatol 120 (2003), 627–632.
[3] K. Asumalahti, T. Latinen, M.L. Ikonen-Vatjus, R Lokki, S. Suomela et al., A candidate gene for psoriasis near HLA-C, HCR (Pg8), is highly polymorphic with a disease-associated susceptibility allele, Hum Mol Genet 9 (2000), 1533–1542.
[4] K. Asumalahti, C. Veal, T. Latinen, S. Snomela, M. Allen et al., Coding haplotype analysis supports HCR as the putative susceptibility gene for Psoriasis at the MHC PSORS1 locus, Hum Mol Genet 11 (2002), 599–597.
[5] N. Balandrendr, R.L. Clough, J.R. Arguello, R. Barber, C. Veal et al., Characterization of the major susceptibility region for psoriasis at chromosome 6p21.3, J Invest Dermatol 113 (1999), 325–328.
[6] A.M. Bowcock, The Genetics of Psoriasis and Auto-immunity, Ann Rev Genomics Human Genetics 6 (2005), 93–122.
[7] A.M. Bowcock and W.O.C.M. Cookson, The genetics of psoriasis, psoriatic arthritis and atopic dermatitis, Hum Mol Genet 13 (2004), R43–R55.
[8] F. Brandrup, N. Holm, N. Grunnet, K. Henningsen and H.E. Hansen, Psoriasis in monozygotic twins: variations in expression in individuals with identical genetic constitution, Acta Derm Venereol 62 (1982), 229–236.
[9] A.D. Burden, S. Javed, M. Bailey, M. Hodgins, M. Connor and D. Tiffin, Genetics of psoriasis: paternal inheritance and a locus on chromosome 6p, J Invest Dermatol 110 (1998), 958–960.
[10] F. Capon, J.K. Toal, J.C. Evans, M.H. Allen, S. Patel et al., Haplotype analysis of distantly related populations implicates coccodesmosin in psoriasis susceptibility, J Med Genet 40 (2003), 447–452.
[11] L. Carlen, K. Sakuraba, M. Stahle and F. Sanchez, HLA-C expression pattern is spatial different between psoriasis and eczema skin lesions, J Invest Dermatol 127 (2007), 342–348.
[12] Y.T. Chang, Y.M. Shiao, P.J. Chin, Y.L. Liu, F.C. Chou et al., Genetic polymorphisms of the HCR gene and a genomic segment in close proximity to HLA-C are associated with patients with psoriasis in Taiwan, Br J Dermatol 150 (2004), 1104–1111.
[13] E. Christophers and T. Henseler, Psoriasis type I and type II as subtypes of nonpustular psoriasis, in: Psoriasis, (2nd ed.), H. Roenigk and H. Maibach, eds, Marcel Dekker Inc., New York, 1990, pp. 15–21.
[14] S. Dogra and S. Yadav, Psoriasis in India: prevalence and pattern, Ind J Dermatol Venereol Leprol 76 (2010), 595–601.
[15] D.L. Duffy, L.S. Spelman and N.G. Martin, Psoriasis in Australian Twins, J Am Acad Dermatol 29 (1993), 428–434.
J.T. Elder, R.P. Nair, T. Henseler, S. Jenisch, P. Stuart et al., The genetics of psoriasis on chromosome 6p and evidence for further disease loci in a 70-Kb interval around the corneodesmosin gene (CDSN), Invest Dermatol 118 (2002), 554–564.

R.C. Trembath, R.L. Clough, J.L. Rosbotham, A.B. Jones, R.D.R. Camp et al., Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis, Hum Mol Genet 6 (1997), 813–820.

C.D. Veal, F. Capon, M.H. Allen, E.K. Health, J.C. Evans et al., Family Based Analysis using a Dense Single Nucleotide Polymorphism – Based Map Defines Genetic Variation at PSORS1, the major psoriasis susceptibility locus, J Invest Dermatol 71 (2002), 554–564.